CHMP recommends expanded approval of Dupixent
The EMA’s expert committee has cleared Sanofi and Regeneron’s atopic dermatitis drug, Dupixent, for children as young as six months.
by albert rønning-andersson, translated by daniel pedersen
On Thursday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) cleared an indication expansion of Dupixent (dupilumab), an atopic dermatitis drug developed by Sanofi and Regeneron.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP rounds off 2022 with five recommendations
For subscribers
.jpg&w=384&q=75)
